About Dexter Formulation Private Limited
Data last updated:
Dexter Formulation Private Limited is a private limited company based in Mayiladuthurai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 April 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U33110TN2009PTC071429.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was formerly known as Dexter Formulations Private Limited. It is led by directors Sivaraman Vijay (Managing Director) and Rajamohan Yamuna.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Old No.60 New No.50 Senbaga Street Besant Nagar, Mayiladuthurai, Tamil Nadu, India – 609001.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.18 Cr, a decline of 32% compared to the previous year. For the same year it recorded a net profit of ₹1.24 Lakh (net margin 1%) and EBITDA of ₹5.7 Lakh (EBITDA margin 4.8%). Revenue has grown at a compounded annual rate (CAGR) of 19% over five years.
As per MCA filings, the company has open charges of ₹26 Lakh on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website dexter.co.in.
Company details
Contact details
Dexter Formulation Private Limited's registered office is in Mayiladuthurai, Tamil Nadu. Its website is dexter.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressOld No.60 New No.50 Senbaga Street Besant Nagar, Mayiladuthurai, Tamil Nadu, India – 609001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dexter Formulation Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Dexter Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Dexter Formulation Private Limited, buy the company report.
Financials of Dexter Formulation Private Limited
FY 2025 filings availableDexter Formulation Private Limited reported revenue of ₹1.18 Cr (down 32% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 32% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 19%. EBITDA fell 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.7 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.24 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.8% | ||||
| Net Profit Margin | 1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dexter Formulation Private Limited, buy the company report.
Board of directors of Dexter Formulation Private Limited
Dexter Formulation has 2 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sivaraman Vijay | Managing Director | 23 Apr 2009 | 17 Years 6 Months | Current |
| Rajamohan Yamuna | Director | 31 Oct 2014 | 12 Years 0 Months | Current |
Peer comparison
Dexter Formulation Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Valphar Lifesciences Private Limited | ₹1.18 Cr (FY 2024) | 26.0% | Ahmedabad, Gujarat, India | |||
| Curactive Life Sciences Private Limited | ₹1.18 Cr (FY 2023) | 769.0% | Vadodara, Gujarat, India | |||
| Dexter Formulation Private Limitedthis company | ₹1.18 Cr (FY 2025) | ₹1.24 Lakh | 1% | -32.0% | Mayiladuthurai, Tamil Nadu, India | |
| Cardeon Formulations Private Limited | ₹1.18 Cr (FY 2025) | 9.0% | Chennai, Tamil Nadu, India | |||
| Xperia Healthcare Private Limited | ₹1.18 Cr (FY 2024) | -5.0% | Vasai, Maharashtra, India |
To see the full peer comparison of Dexter Formulation Private Limited, buy the company report.
Auditor
Dexter Formulation Private Limited is audited by R.SATTAINATHAN & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R.SATTAINATHAN & ASSOCIATES | FY 2023 | 213461 |
Shareholding
The shareholding of Dexter Formulation Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2015 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dexter Formulation Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 May 2024 | 100925753 | Indian Bank | ₹26 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Dexter Formulation Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dexter Formulation Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Dexter Formulation Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Dexter Formulation Private Limited has 12 board changes on record since 2009: 7 appointments and 5 cessations. The latest: Henry Doss Maria Gnanaprakasam ceased to be Director on 14 Nov 2018.
4 earlier events are in the company report.
Frequently asked questions
Dexter Formulation is an active private limited company based in Mayiladuthurai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 April 2009 (17+ years old) and is registered under CIN U33110TN2009PTC071429.
Dexter Formulation has 2 current directors:
- Sivaraman Vijay - Managing Director
- Rajamohan Yamuna - Director
The latest financial statements of Dexter Formulation on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Dexter Formulation is U33110TN2009PTC071429. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dexter Formulation was incorporated on 23 April 2009, making it 17+ years old. It is registered with the Registrar of Companies, Chennai.
The peers of Dexter Formulation by revenue are Valphar Lifesciences Private Limited, Curactive Life Sciences Private Limited, Cardeon Formulations Private Limited, Xperia Healthcare Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Henry Doss Maria Gnanaprakasam ceased to be Director on 14 Nov 2018. Henry Doss Maria Gnanaprakasam was appointed as Director on 09 Mar 2018. Shankar ceased to be Director on 09 Mar 2018. Dexter Formulation has 12 board changes on record in total.
Dexter Formulation can be reached through the website dexter.co.in. Its registered office is in Mayiladuthurai, Tamil Nadu, India.
The registered office of Dexter Formulation is at Old No.60 New No.50 Senbaga Street Besant Nagar, Mayiladuthurai, Tamil Nadu, India – 609001.
Dexter Formulation operates in the pharma industry, in the drug formulation and development segment.
Dexter Formulation has open charges of ₹26 Lakh and no satisfied charges on record as per latest MCA filings.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
